2026-04-17T16:06:00Zhttps://recercat.cat/oai/request
oai:recercat.cat:10459.1/4688232025-10-20T18:03:44Zcom_2072_3622col_2072_479130
RECERCAT author Garcia-Guiñón, Antoni author Charry, Paola Andrea author Jimenez, María author Sarra, Josep author Delgado, Izarbe author Segura de la Torre, Laura author Santaliestra, Marta author Garcia-Pintos, Marta author Gonzalez, Yolanda author Senin, Alicia author Motlló, Cristina author Abella, Eugènia author Cabezudo, Elena author Granell, Miquel author Sancho, Esther author Herranz, María José author Seres, Yasmina author Gironella, Mercedes author Soler, Juan Alfons author Marti-Tutusaus, Josep Maria author Ben Azaiz, Ran author Fernandez de Larrea, Carlos 2025-10-20T18:03:43Z 2025-10-20T18:03:43Z 2025 http://hdl.handle.net/10459.1/468823 Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM. cc-by-nc (c) The Authors, 2025 Attribution-NonCommercial 4.0 International info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc/4.0/ Carfilzomib, lenalidomide and dexamethasone Real-world Relapsed/refractory multiple myeloma Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion